DCP
DGX icon

Distillate Capital Partners’s Quest Diagnostics DGX Stock Holding History

Distillate Capital Partners’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-88,756
Closed -$15.4M – 130
2025
Q4 		$15.4M Buy
+88,756
New +$16.2M 0.79% 61
2025
Q3 		– Sell
-93,774
Closed -$16.8M – 125
2025
Q2 		$16.8M Sell
93,774
-4,577
-5% -$795K 0.9% 40
2025
Q1 		$16.6M Sell
98,351
-6,752
-6% -$1.11M 0.85% 45
2024
Q4 		$15.9M Sell
105,103
-913
-0.9% -$142K 0.78% 67
2024
Q3 		$16.5M Buy
+106,016
New +$15.8M 0.82% 50
2021
Q1 		– Sell
-12,567
Closed -$1.49M – 120
2020
Q4 		$1.49M Buy
+12,567
New +$1.53M 0.71% 86

Other funds holding DGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return

Distillate Capital Partners's DGX Position: Q1 2026 in Review

Distillate Capital Partners sold out of Quest Diagnostics (DGX) in Q1 2026, closing a stake of 88,756 shares — an estimated $15.4M sold.

Distillate Capital Partners first reported a position in DGX in Q4 2020 and held it in 6 quarters. The position peaked at $16.8M in Q2 2025. 1,064 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

  • Distillate Capital Partners reported no remaining Quest Diagnostics position as of Q1 2026 after selling out during the quarter.
  • Distillate Capital Partners sold 88,756 Quest Diagnostics shares in Q1 2026, an estimated $15.4M.
  • Distillate Capital Partners first reported a position in Quest Diagnostics in Q4 2020 and held it in 6 quarters.
  • Distillate Capital Partners's Quest Diagnostics position peaked at $16.8M in Q2 2025.
  • 1,064 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on Distillate Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.